Study reviews the role of a ribonucleic acid 'MALAT1' in hematological malignancies

by Cactus CommunicationsRecent studies have shown that an abnormally high expression of MALAT1 in blood cancer cells could aid the chemotherapeutic resistance development through multiple intermolecul

Updated on: April 28,2024

Study reviews the role of a ribonucleic acid 'MALAT1' in hematological malignancies

by Cactus CommunicationsRecent studies have shown that an abnormally high expression of MALAT1 in blood cancer cells could aid the chemotherapeutic resistance development through multiple intermolecul

Updated on:April 28,2024

Engineering the immune system to tackle glioblastoma

by Sally Sapega,University of PennsylvaniaCredit: University of PennsylvaniaEach year, roughly 15,000 Americans are diagnosed with Glioblastoma Multiforme (GBM), the most common malignant primar

Updated on: December 22,2023

Engineering the immune system to tackle glioblastoma

by Sally Sapega,University of PennsylvaniaCredit: University of PennsylvaniaEach year, roughly 15,000 Americans are diagnosed with Glioblastoma Multiforme (GBM), the most common malignant primar

Updated on:December 22,2023

UGN-101 reviewed in real-world upper tract urothelial cancer setting

by Elana GotkineFor patients with upper tract urothelial cancers (UTUCs), the novel therapeutic UGN-101 seems to be effective, with an acceptable safety profile, according to research published online

Updated on: December 17,2023

UGN-101 reviewed in real-world upper tract urothelial cancer setting

by Elana GotkineFor patients with upper tract urothelial cancers (UTUCs), the novel therapeutic UGN-101 seems to be effective, with an acceptable safety profile, according to research published online

Updated on:December 17,2023

Targeting specific genomic mutation in breast cancer improves outcomes, first study shows

byEuropean Society for Medical OncologyFabrice André, oncologist and Professor of Medical Oncology at the Institut Gustave Roussy, Villejuif, France, study author. Credit: © European Society for

Updated on: December 18,2023

Targeting specific genomic mutation in breast cancer improves outcomes, first study shows

byEuropean Society for Medical OncologyFabrice André, oncologist and Professor of Medical Oncology at the Institut Gustave Roussy, Villejuif, France, study author. Credit: © European Society for

Updated on:December 18,2023

Multisite multiomic analysis reveals diverse resistance mechanisms in end-stage ovarian cancer

by Justin Jackson , Medical XpressThe clinical journey is shown for each patient, in 100 day intervals (x-axis), with the first tick referring to the day of first diagnostic information (surgery or CA

Updated on: December 21,2023

Multisite multiomic analysis reveals diverse resistance mechanisms in end-stage ovarian cancer

by Justin Jackson , Medical XpressThe clinical journey is shown for each patient, in 100 day intervals (x-axis), with the first tick referring to the day of first diagnostic information (surgery or CA

Updated on:December 21,2023

Tail spin: Study reveals new way to reduce friendly fire in cell therapy

by Bill Hathaway,Yale UniversityIn CAR-T therapy, T cells in blue find antigens (red) and kill cancer cells (purple). But often, antigens attach to other T cells leading other T cells to attack

Updated on: January 08,2024

Tail spin: Study reveals new way to reduce friendly fire in cell therapy

by Bill Hathaway,Yale UniversityIn CAR-T therapy, T cells in blue find antigens (red) and kill cancer cells (purple). But often, antigens attach to other T cells leading other T cells to attack

Updated on:January 08,2024

Nab-paclitaxel does not extend biliary tract cancer survival, but may benefit some

by SWOG Cancer Research NetworkCredit: Pixabay/CC0 Public DomainAdding nab-paclitaxel to a standard treatment of gemcitabine plus cisplatin does not significantly extend median overall survival (OS) t

Updated on: December 17,2023

Nab-paclitaxel does not extend biliary tract cancer survival, but may benefit some

by SWOG Cancer Research NetworkCredit: Pixabay/CC0 Public DomainAdding nab-paclitaxel to a standard treatment of gemcitabine plus cisplatin does not significantly extend median overall survival (OS) t

Updated on:December 17,2023

Predicting lymphoma patients' treatment outcomes

byCedars-Sinai Medical CenterDistinct spatially resolved TME features according to relapse status. (A) Proportion for the indicated immune cell population by IMC-based cluster assignment. (B) Th

Updated on: December 26,2023

Predicting lymphoma patients' treatment outcomes

byCedars-Sinai Medical CenterDistinct spatially resolved TME features according to relapse status. (A) Proportion for the indicated immune cell population by IMC-based cluster assignment. (B) Th

Updated on:December 26,2023

B cells linked to effective cancer immunotherapy

by Göran B Jönsson,Lund UniversityImmunofluorescence analysis of a melanoma tumor showing that B cells in B cell clusters express CXCR5, a marker for tertiary lymphoid structures. Credit: Göran

Updated on: December 20,2023

B cells linked to effective cancer immunotherapy

by Göran B Jönsson,Lund UniversityImmunofluorescence analysis of a melanoma tumor showing that B cells in B cell clusters express CXCR5, a marker for tertiary lymphoid structures. Credit: Göran

Updated on:December 20,2023

Pembrolizumab Monotherapy Displays Efficacy in Rare Sarcomas

The PD-1 inhibitor pembrolizumab (Keytruda) displayed activity with a manageable safety profile in patients with certain rare and ultra-raresarcoma histotypes, according to findings from the phase 2 A

Updated on: November 07,2023

Pembrolizumab Monotherapy Displays Efficacy in Rare Sarcomas

The PD-1 inhibitor pembrolizumab (Keytruda) displayed activity with a manageable safety profile in patients with certain rare and ultra-raresarcoma histotypes, according to findings from the phase 2 A

Updated on:November 07,2023

How a patient partnership is propelling cancer research

by Leah Eisenstadt,Broad Institute of MIT and HarvardCount Me In Director Nikhil Wagle and Strategic Advisor Corrie Painter. Credit: Broad Institute of MIT and HarvardIn the fall of 2018, cancer

Updated on: December 19,2023

How a patient partnership is propelling cancer research

by Leah Eisenstadt,Broad Institute of MIT and HarvardCount Me In Director Nikhil Wagle and Strategic Advisor Corrie Painter. Credit: Broad Institute of MIT and HarvardIn the fall of 2018, cancer

Updated on:December 19,2023

Study shows AI improves accuracy of skin cancer diagnoses

by Krista Conger,Stanford UniversityCredit: CC0 Public DomainA new study led by researchers at Stanford Medicine finds that computer algorithms powered by artificial intelligence based on deep l

Updated on: April 30,2024

Study shows AI improves accuracy of skin cancer diagnoses

by Krista Conger,Stanford UniversityCredit: CC0 Public DomainA new study led by researchers at Stanford Medicine finds that computer algorithms powered by artificial intelligence based on deep l

Updated on:April 30,2024